Obstetrics and Gynaecology

CO2 Laser With Clobetasol for Vulvar Lichen Sclerosus

Published on Nov 18, 2026
3 min read
CO2 Laser With Clobetasol for Vulvar Lichen Sclerosus - OC Academy Medical Insights
"A multicenter trial assesses fractionated CO2 laser with clobetasol for vulvar lichen sclerosus. Discover the key clinical findings and symptom outcomes."

Managing vulvar lichen sclerosus remains a major clinical challenge for gynecologists and dermatologists. Currently, topical corticosteroids serve as the primary standard of care. However, many clinicians explore adjunctive modalities like energy-based devices. Consequently, researchers evaluated whether adding fractionated carbon dioxide laser therapy improves clinical outcomes.

Trial Design for Vulvar Lichen Sclerosus

This multicenter, double-blind, randomized trial enrolled adult women across nine sites in the United States. Specifically, investigators recruited patients who elected fractionated carbon dioxide laser treatment for their condition. The team excluded patients with prior pelvic radiation, vaginal mesh repair, or systemic immunomodulator therapy. Furthermore, investigators excluded pregnant individuals and those with suspected malignancies.

All participants received three laser sessions scheduled four to six weeks apart. Additionally, participants applied either clobetasol propionate 0.05% ointment or a placebo ointment nightly for four weeks. Subsequently, they transitioned to a twice-weekly maintenance schedule. The primary outcome was a 16-point or greater improvement on the validated Skindex-29 questionnaire.

Key Efficacy and Symptom Findings

The study analyzed 180 participants who completed full evaluation protocols. Notably, nearly one-third of all patients achieved the primary Skindex-29 threshold. Specifically, 30.3% of patients in the clobetasol arm achieved this milestone compared to 27.5% in the placebo arm. However, this difference did not reach statistical significance.

Nevertheless, participants receiving clobetasol achieved significantly greater reductions in symptom domain scores. Their mean symptom score improved by 19.0 points versus 10.1 points in the placebo cohort. Therefore, topical clobetasol provided measurable symptom relief beyond laser therapy alone. Both treatment arms demonstrated high patient satisfaction rates without unexpected adverse reactions.

Clinical Takeaways for Practitioners

These findings carry valuable practical insights for everyday clinical practice. First, topical corticosteroids remain an indispensable element of disease management. While laser therapy attracts growing interest, procedural interventions should not replace evidence-based medical therapy. Instead, clinicians must emphasize adherent topical steroid therapy to optimize symptom control.

Moreover, clinicians should counsel patients regarding realistic treatment expectations. Combining procedural modalities with topical ointments relieves certain symptoms, but it does not dramatically change overall quality of life. Consequently, careful patient selection and thorough counseling remain essential.

Frequently Asked Questions

Q1: Does adding fractionated CO2 laser eliminate the need for topical clobetasol?

No, clinical evidence demonstrates that topical clobetasol remains necessary. Patients using concomitant clobetasol achieved significantly greater symptom reduction than those receiving laser therapy alone.

Q2: What was the primary outcome of the randomized trial?

The primary outcome was the proportion of patients achieving at least a 16-point improvement on the Skindex-29 questionnaire. However, the trial showed no statistically significant difference between the clobetasol and placebo arms for this broad metric.

Q3: How safe was the combination of laser therapy and clobetasol?

Both treatment arms demonstrated excellent safety profiles. Furthermore, investigators reported high patient satisfaction rates and no unexpected adverse events throughout the study follow-up.

References

  1. Dieter AA et al. A Randomized Trial of Fractionated CO2 Laser With Topical Clobetasol Compared With Fractionated CO2 Laser With Placebo for Treatment of Vulvar Lichen Sclerosus. Obstet Gynecol. 2026 Nov 17. doi: 10.1097/AOG.0000000000006476. PMID: 43044089.
  2. Gil-Villalba A, Ayen-Rodriguez A, Naranjo-Diaz MJ, Ruiz-Villaverde R. Laser Therapy for Vulvar Lichen Sclerosus, a Systematic Review. Life (Basel). 2023;13(11):2146.
  3. Burkett L, et al. Clobetasol Compared With Fractionated Carbon Dioxide Laser for Lichen Sclerosus. Obstet Gynecol. 2021;137(6):968-974.

Related Articles You May Like